Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab-based therapy in PD-1 inhibitor-pretreated solid tumors
ChiCTR2500101300Phase 2Recruiting
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Nonhematologic neoplasms, sponsored by First People's Hospital of Lianyungang City. Primary endpoint: Progression-free survival. Started Apr 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500101300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101300.